About Keratin, type I cytoskeletal 13
Keratin, type I cytoskeletal 13 (KRT13) is a protein
from Homo sapiens identified by UniProt accession
P13646, 458 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 13 |
| UniProt accession | P13646 |
| Gene | KRT13 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (138)
Diseases linked to this target (Open Targets).
- White sponge nevus · score 0.55
- genetic disorder · score 0.19
- head and neck squamous cell carcinoma · score 0.19
- glioblastoma multiforme · score 0.19
- clear cell renal carcinoma · score 0.18
- pancreatic adenocarcinoma · score 0.18
- ovarian cancer · score 0.18
- esophageal cancer · score 0.15
- white sponge nevus 1 · score 0.13
- oral squamous cell carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P13646-F1 | alphafold | PREDICTED | 72.59 | — |
Amino-acid sequence (458 residues)
MSLRLQSSSA SYGGGFGGGS CQLGGGRGVS TCSTRFVSGG SAGGYGGGVS CGFGGGAGSG FGGGYGGGLG GGYGGGLGGG FGGGFAGGFV DFGACDGGLL TGNEKITMQN LNDRLASYLE KVRALEEANA DLEVKIRDWH LKQSPASPER DYSPYYKTIE ELRDKILTAT IENNRVILEI DNARLAADDF RLKYENELAL RQSVEADING LRRVLDELTL SKTDLEMQIE SLNEELAYMK KNHEEEMKEF SNQVVGQVNV EMDATPGIDL TRVLAEMREQ YEAMAERNRR DAEEWFHTKS AELNKEVSTN TAMIQTSKTE ITELRRTLQG LEIELQSQLS MKAGLENTVA ETECRYALQL QQIQGLISSI EAQLSELRSE MECQNQEYKM LLDIKTRLEQ EIATYRSLLE GQDAKMIGFP SSAGSVSPRS TSVTTTSSAS VTTTSNASGR RTSDVRRP
Explore Keratin, type I cytoskeletal 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets